Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Sicherheits- und Verträglichkeitsstudie von ST-503 bei kleinen Faser-Neuropathie-assoziierten feuerfestigen Schmerzen

30. Oktober 2026 aktualisiert von: Sangamo Therapeutics

Eine multizentrische doppelblinde, randomisierte, schein kontrollierte Dosis-Eskalationsstudie zur Bestimmung der Sicherheit und Verträglichkeit von intrathekalen ST-503-Gentherapie bei refraktären Schmerzen aufgrund idiopathischer kleiner Faserneuropathie (ISFN)

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

Studienübersicht

Detaillierte Beschreibung

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.

Studientyp

Interventionell

Einschreibung (Geschätzt)

27

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Arizona
      • Scottsdale, Arizona, Vereinigte Staaten, 85260
        • HonorHealth
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72205
        • University of Arkansas for Medical Sciences
    • California
      • La Jolla, California, Vereinigte Staaten, 92093
        • The University of California, San Diego
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21218
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02114
        • Massachusetts General Hospital
    • New Hampshire
      • Lebanon, New Hampshire, Vereinigte Staaten, 03766
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York, New York, Vereinigte Staaten, 10027
        • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27514
        • University of North Carolina Medical Center
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37235
        • Vanderbilt University
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84112
        • University of Utah
    • Virginia
      • Richmond, Virginia, Vereinigte Staaten, 23284
        • Virginia Commonwealth University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria

  1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
  2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
  3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit

Exclusion Criteria

  1. Drug- and alcohol-related:

    1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
    2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
    3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
    4. Use of cannabinoids is not permitted.
  2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies

  3. Procedure-related:

    1. Contraindications to LP, general anesthesia or sedation
    2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
  4. Infectious disease-related:

    1. Active viral infection or bacterial
    2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
  5. Hepatic disease- and hepatotoxic medication-related:

    1. Presence of clinically relevant liver disease
    2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
    3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
    4. Hepatotoxic supplement use during the study period
  6. Cancer-related:

    a. History of cancer, including B-cell cancers, within 5 years of Screening

    i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months

    b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation

  7. Previously received gene or cellular therapy

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Schein-Komparator: Schein kontrollierte Studie

Sham Procedure

Experimental: Untersuchungsagent

Genomic Medicine

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence and severity of treatment emergent adverse events (TEAEs)
Zeitfenster: 12 weeks

To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.

12 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of subjects with pain intensity reduction from baseline at Week 12
Zeitfenster: 12 weeks
  • 30% in the weekly average of daily pain intensity measurements performed using the PI-NRS

  • 50% in the weekly average of daily pain intensity measurements performed using the PI-NRS

    • Dose of rescue medication use
    • Frequency of rescue medication use
12 weeks
Percentage of subjects at Week 12
Zeitfenster: 12 weeks
  • Categorized as improved on the patient global impression of change (PGIC) assessment
  • With a ≥ 1-point improvement in suicidal ideation in Columbia Suicide Severity Rating Scale (C-SSRS) responses
12 weeks
Columbia Suicide Severity Rating Scale (CSSRS) Rating
Zeitfenster: 12 weeks

With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses

12 weeks
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
Zeitfenster: 12 Weeks

Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary.

12 Weeks
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
Zeitfenster: 12 Weeks

This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week.

12 Weeks
Daily Sleep Interference Score (DSIS)
Zeitfenster: 12 Weeks

DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe).

12 Weeks
Hospital Anxiety and Depression Scale (HADS)
Zeitfenster: 12 Weeks

HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms.

12 Weeks
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
Zeitfenster: 12 Weeks

The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms.

12 Weeks
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
Zeitfenster: 12 Weeks

The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability.

12 Weeks
36-Item Short Form Health Survey (SF-36) domains and summary scores
Zeitfenster: 12 Weeks

This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life.

12 Weeks
Pain Catastrophizing Questionnaire (PCS)
Zeitfenster: 12 Weeks

PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present.

12 Weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Medical Monitor, Sangamo Therapeutics Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Dezember 2025

Primärer Abschluss (Geschätzt)

1. Juli 2027

Studienabschluss (Geschätzt)

1. Juli 2028

Studienanmeldedaten

Zuerst eingereicht

30. April 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Mai 2025

Zuerst gepostet (Tatsächlich)

20. Mai 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren